Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti-interleukin-1beta monoclonal antibody. METHODS: We performed a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS. In part 1, 35 patients received 150 mg of canakinumab subcutaneously. Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 weeks for up to 24 weeks. After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab. We evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA). RESULTS: In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab. Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission. Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P<0.001). At the end of part 2, median CRP and SAA values were normal (<10 mg per liter for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P<0.001 and P=0.002, respectively). Of the 31 patients, 28 (90%) completed part 3 in remission. In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo. CONCLUSIONS: Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, IL-1RA-blocking Ab (anakinra) and IL-1β-blocking Ab (canakinumab) are already FDA approved as anti-inflammatory biologics for the treatment of rheumatoid arthritis (130) and NLRP3-inflammasome-mediated cryopyrin-associated periodic syndrome (CAPS) (131), respectively.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [131]
Citations
Cites
Natural History and Outcome in Systemic AA Amyloidosis
Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,032
Self-citationSpectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. F. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 744
Self-citationHoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577 · cited 2×
“Viral infection 0 2 (13) 0 0 Headache 0 2 (13) 0 3 ( 10 )”
URTICARIA, DEAFNESS, AND AMYLOIDOSIS: A NEW HEREDO-FAMILIAL SYNDROME
(1962) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a066967 · Cited by 372
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Self-citationPrimer: inflammasomes and interleukin 1β in inflammatory disorders
Church, L. D., Cook, G. P., & McDermott, M. F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0681 · Cited by 309
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Bijlsma, J. W. J., Dougados, M., Emery, P., Keystone, E. C., Klareskog, L., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044941 · Cited by 225
Leslie, K. S., Lachmann, H. J., Bruning, E., McGrath, J. A., Bybee, A., Gallimore, J. R., Roberts, P. F., Woo, P., Grattan, C. E., & Hawkins, P. N. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.12.1591 · Cited by 186 · cited 13×
“Rhinitis 4 (11) 1 (7) 2 (12) 0 Bronchitis 3 (9) 1 ( 7 ) 1 (6) 0”
InfluentialSelf-citationAlten, R., Gram, H., Joosten, L. A., Berg, W. B. V. D., Sieper, J., Wassenberg, S., Burmester, G., van Riel, P., Diaz-Lorente, M., Bruin, G. J., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2438 · Cited by 170
The many worlds of reducing interleukin‐1
Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21107 · Cited by 104
Research works printed but not linked: 5
- Muckle TJ, 1962, Q J Med, 31, 235
- Lachmann HJ, 2008, Clin Exp Rheumatol, 26, 181
- Kuemmerle-Deschner JB, 2008, Clin Exp Rheumatol, 26, 180
- Kummerle-Deschner J, 2008, Ann Rheum Dis, 67, 104
- Maier J, 2008, J Rheumatol, 35, 939
Cited by
Items 701–800 of 869
Naik, H. B., Ombrello, A. K., & Cowen, E. W. (2017) · Springer eBooks · doi:10.1007/978-3-319-29785-9_40 · Cited by 1
Skin Signs of Other Systemic Diseases
Paller, A. S., & Mancini, A. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-24475-6.00025-x · Cited by 1
The Pathogenesis of Antineutrophil Cytoplasmic Antibody Renal Vasculitis
Lee, S. C. L., Roger, S., & Andrew, S. (2013) · InTech eBooks · doi:10.5772/54637 · Cited by 2
“This is clinically relevant because diseases resulting from overstimulation of the Inflammasome have been successfully treated with monoclonal antibody therapy.[136] This warrants further investigation.”
BackgroundNiccoli, L., Cassarà, E. A. M., KALOUDI, O., Nannini, C., Romagnoli, M., & Cantini, F. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0602-6 · Cited by 2
“Based on the consistent body of evidence of the pathogenic role of inflammasome-dependent release of IL-1beta in patients with asbestosis and related systemic autoimmune disease, we decided to treat our patient with canakinumab, a specifically targeted anti-IL-1beta antibody, which has been licensed for the treatment…”
BackgroundP02-027 - Quality of life in CAPS treated by Canakinumab
Marsaud, C., Marie, I., & Koné‐Paut, I. (2013) · Pediatric Rheumatology · doi:10.1186/1546-0096-11-s1-a134 · Cited by 1
“Methods Patients were those first included in the pivotal (D2304) and in the extension (D2306) Canakinumab/CAPS study [1] and followed in the reference center for autoinflammatory diseases at Bicêtre Hospital (Paris).”
BackgroundNew and emerging therapies for gout
Crittenden, D. B., Kim, H. N., Fisher, M. C., Goldfarb, D. S., & Pillinger, M. H. (2011) · Clinical Investigation · doi:10.4155/cli.11.143 · Cited by 1
Current options for the treatment of cryopyrin-associated periodic syndromes
Galeotti, C., & Koné‐Paut, I. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.821946 · Cited by 1
“Thirty-five patients, carrying essentially MWS phenotype received an injection of 150 mg canakinumab for adults and 2 mg/kg in children [39].”
MethodTRANSLATIONAL MEDICINE: DEFINITION, HISTORY, AND STRATEGIES
Littman, B. H. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976087.003 · Cited by 1
Santos, M. J., Canhão, H. M., Conde, M., Fonseca, J. E., Mourão, A. F., Oliveira‐Ramos, F., Costa, L. M. S. F., Ramos, M. P., Cabral, M., Estanqueiro, P., et al. (2012) · PubMed · Cited by 1
Inflammasomopathies: Diseases Linked to the NLRP3 Inflammasome
Nardo, D. D., Vogelhuber, J., Labzin, L. I., Langhoff, P., & Latz, E. (2012) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814355698_0002 · Cited by 1
Neonatal-Onset Urticaria and Fever
Marsili, M., Battista, C. D., Chiarelli, F., Breda, L., Ceccherini, I., & Gattorno, M. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.07.004 · Cited by 1
Dusser, P., Marsaud, C., & Koné‐Paut, I. (2015) · Cited by 1
Other Biological Therapies for Pediatric Rheumatic Diseases
Сантимов, А. В., & Grom, A. A. (2016) · Technical report · doi:10.1016/b978-0-444-63596-9.00024-4 · Cited by 2
An update: current and prospective treatments for adult-onset Still’s disease
Kim, H., & Suh, C. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1311252 · Cited by 1
Interleukin (IL)-1 Blocking Compounds and Their Use in Autoinflammatory Diseases
Kallinich, T., & Benedetti, F. D. (2019) · Springer eBooks · doi:10.1007/978-3-319-98605-0_41 · Cited by 1
Interference of canakinumab with commercial IL-1β ELISAs
Linge, M., Hedrich, C. M., Rösen‐Wolff, A., & Winkler, S. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.05.008 · Cited by 1
Eisenberg, R. A., & Behrens, E. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-29875-9.00017-3 · Cited by 1
Dedeoğlu, F., & Kim, H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-29875-9.00014-8 · Cited by 1
Tomelleri, A., Campochiaro, C., Luca, G. D. D., Farina, N., Cavalli, G., & Dagna, L. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1904395 · Cited by 1
“a single subcutaneous injection every 4 weeks, with the exception of cryopyrin-associated periodic syndromes (every 8 weeks) [51].”
BackgroundOmbrello, A. K., & Aksentijevich, I. A. (2015) · Current clinical pathology · doi:10.1007/978-3-319-19294-9_3 · Cited by 1
Monoclonal Antibodies as Therapeutic Agents
Khan, M. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-30273-7_5 · Cited by 1
New drugs: Eltrombopag olamine
(2011) · Australian Prescriber · doi:10.18773/austprescr.2011.033 · Cited by 1
Lee, S. (2014) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2014.21.5.228 · Cited by 1
Management of autoinflammatory syndromes and periodic fevers
Peet, C. J., & Lachmann, H. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95061-9.00049-7 · Cited by 2
Self-citationGenetics of autoinflammation instructs selective IL-1 targeting
Garlanda, C., & Supino, D. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.010 · Cited by 1
A Review of the Role of Canakinumab - An Anti-Inflammatory Agent in CAD
Olayinka, J., Okoye, C., & Amarachi, O. (2023) · International Journal of Health Sciences and Research · doi:10.52403/ijhsr.20230909 · Cited by 1
Periodic Fever Syndromes in Children and Hearing Loss
Öztürk, K., Sönmez, H. E., & Kasapçopur, Ö. (2023) · Comprehensive ENT · doi:10.1007/978-3-031-38495-0_66 · Cited by 1
Taneda, T., Takahashi, M., 梅田, 麻., Umeda, Y., Oyake, M., Nishikomori, R., & Fujita, N. (2024) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-001956 · Cited by 1
Les maladies auto-inflammatoires chez l’enfant
Koné‐Paut, I. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.11.022 · Cited by 1
Burden of fatigue in cryopyrin-associated periodic syndromes
Şatırer, Ö., Satirer, Y., Gellner, A., Benseler, S. M., & Kuemmerle-Deschner, J. B. (2025) · EULAR Rheumatology Open · doi:10.1016/j.ero.2025.03.003 · Cited by 1
“Categories of clinical disease activity were determined by PGA and PPGA on a 10 cm VAS and categorised as mild ( < 2), moderate (2-4), and high ( > 4) as described previously [14].”
Self-citationHereditary periodic fever syndromes in adult rheumatology practice
Zhelyabina, O. V., Елисеев, М. С., & Chikina, M. N. (2018) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2018-1-78-84 · Cited by 1
The journey of canakinumab; on- and off-label indications
Marotto, D., Batticciotto, A., Ceribelli, A., & Sarzi‐Puttini, P. (2019) · Beyond Rheumatology · doi:10.4081/br.2019.4 · Cited by 1
Is there any treatment for inflammatory amyloidosis?
Stankovic, K., & Grateau, G. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.09.001 · Cited by 1
Nguyen, T. V., & Leslie, K. S. (2013) · Springer eBooks · doi:10.1007/978-3-642-39532-1_7 · Cited by 1
Self-citationRußwurm, M., Johannsen, S., Kortus-Goetze, B., & Haas, C. S. (2024) · Research Square · doi:10.21203/rs.3.rs-3951042/v1 · Cited by 1
Biothérapies en rhumatologie pédiatrique
Quartier, P., Bader‐Meunier, B., & Mouy, R. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0124-7_12
Self-citationErkrankungen mit rezidivierenden Fieberschüben
Horneff, G., & Wahn, V. (2014) · Springer eBooks · doi:10.1007/978-3-642-41814-3_39
Serum Amyloid A (SAA): Proinflammatory functions and their regulation by serum lipoproteins
Niemi, K. (2012) · Helda - University of Helsinki Institutional Repository · Cited by 1
Lifelong urticaria and multiple unexplained systemic symptoms
Newell, L., August, S., Foria, V., & Godfrey, K. M. (2011) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2010.03947.x
Roles in innate immune receptors: Host : pathogen interactions and strengthening vaccines
Nyström, S. (2013) · Figshare
Das familiäre Mittelmeerfieber und andere hereditäre Fiebersyndrome
Max, R., & Blank, N. (2013) · Arthritis und Rheuma · doi:10.1055/s-0037-1618186
“Auch beim TRAPS sind Medikamente, die Interleukin-1 blockieren können, wie Canakinumab, Anakinra oder Rilonacept wirksam.”
BackgroundInfluentialTraitement des maladies auto-inflammatoires : quelles avancées ?
Koné‐Paut, I., Marie, I., Magrhraoui, V., & Tran, T.-A. (2010) · Archives de Pédiatrie · doi:10.1016/s0929-693x(10)70021-x
Berthelot, J., Batard, K., Goff, B. L., & Maugars, Y. (2012) · Revue du Rhumatisme · doi:10.1016/j.rhum.2012.08.012
Quoi de neuf en médecine interne ?
Blétry, O., Sené, T., Kahn, J., Ackermann, F., Charles, P., Leport, J., & Piette, A. M. (2009) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(09)73383-6
Analisi socio-economica di lungo periodo di un paziente con una malattia reumatologica rara (CINCA)
Fattore, G., & Gattorno, M. (2010) · PharmacoEconomics Italian Research Articles · doi:10.1007/bf03320673
Canakinumab for the treatment of adult and pediatric cryopyrin‐associated periodic syndromes (CAPS)
Patel, A. M., & Torok, K. S. (2011) · Drug Development Research · doi:10.1002/ddr.20465
Existe-t-il des traitements de l’amylose inflammatoire ?
Stankovic, K., & Grateau, G. (2010) · Revue du Rhumatisme · doi:10.1016/j.rhum.2010.08.015
Periodic fevers and autoinflammatory conditions
Bakshi, J., & Wilkinson, N. M. (2014) · Paediatrics and Child Health · doi:10.1016/j.paed.2014.04.001
Focus sur les inhibiteurs de l’interleukine 1
Rossi‐Semerano, L., & Koné‐Paut, I. (2011) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2011.09.001
Review of biologics in children with rheumatic diseases
Habibi, S., & Ramanan, A. V. (2012) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.11.75 · Cited by 2
Hormonal regulation of immune modulators in human breast tissue
Morad, V. (2015) · Linköping University medical dissertations · doi:10.3384/diss.diva-117983
Canakinumab: new treatment choice for systemic juvenile idiopathic arthritis
Sözeri, B., Sevgi, S., & Kasapçopur, Ö. (2015) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.14.53
Industry Update: the Latest Developments in Therapeutic Delivery
Rees, G. D. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.7
Canakinumab in autoimmune and autoinflammatory rheumatic diseases
Kadavath, S. M., & Efthimiou, P. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.868802
“, at the dose of 2 mg/kg every 8 weeks can lead to rapid remission of disease in the majority of patients with CAPS; most of the patients treated were adults with an intermediate MWS subtype [31].”
BackgroundRenin-Dependent Hypertension in Mice Requires the NLRP3-
Nussberger, J., Ives, A., Bagnoud, N., Shäefer, S., & Tschopp, J. (2014)
Allergy, cold contact urticarial and cold induced urticaria-like syndromes
Pérez, B. V., Díaz, Á. R., & Sexto, L. V. (2012) · Dialnet (Universidad de la Rioja)
Modern Therapies in AA Amyloidosis
Ombrello, A. K. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-389-3_31
Rhumatologie pédiatrique : quelles avancées ?
Koné‐Paut, I. (2011) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2011.11.008
Basic Science for the Clinician 51
Sigal, L. H. (2011) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e318227e84c
Discovery and Development of Ilaris® for the Treatment of Cryopyrin-Associated Periodic Syndromes
Gram, H. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624202-00185
Канакинумаб в лечении ревматических болезней у детей
Alekseeva, I., & Russian Federation (2014)
[Autoinflammatory diseases reach adolescence].
Eguchi, K., Nonaka, F., & Migita, K. (2013) · PubMed
NLRP3 and Its Role in Autoinflammatory Disorders
Ören, S., Ozafsar, O., & Demirkaya, E. (2016) · Annals of Paediatric Rheumatology · doi:10.5455/apr.062920160541
“It inhibits caspase-1 activation by alkylation of the p20 subunit, and also interferes with NLRP3 ATPase activity [63,67-69].”
BackgroundHereditäre periodische Fiebersyndrome (HPFS)
Moog, P., & Heemann, U. W. (2016) · Der Nephrologe · doi:10.1007/s11560-016-0101-2
Wollenhaupt, J., & Augustin, A. K. S. (2010)
Dedeoğlu, F., & Kim, H. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0271-2.00021-3
Cardiac Effects of Antirheumatic Drugs
Szekanecz, Z. (2017) · Technical report · doi:10.1016/b978-0-12-803997-7.00020-x · Cited by 1
CAPS(Cryopyrin-associated periodic syndrome)クリオピリン関連周期熱症候群
隆太, 西. (2017) · アレルギー · doi:10.15036/arerugi.66.50
Рамеев, В. В., Bogdanova, M. V., Kozlovskaya, L. V., & Mukhin, N. A. (2017) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2017-45-7-605-615
Gram, H. (2016) · Journal of Rare Diseases Research & Treatment · doi:10.29245/2572-9411/2016/1.1006
Advances in the Diagnosis and Treatment of Amyloidosis and Related Disorders
Sayed, R. H. (2018) · UCL Discovery (University College London)
Rare autoinflammatory and miscellaneous diseases
(2018) · Oxford University Press eBooks · doi:10.1093/med/9780198728252.003.0018
Jéru, I. (2018) · Rare rheumatic diseases · doi:10.1007/978-3-319-99139-9_2
Monitoring Disease Activity, Damage and Quality of Life
ter Haar, N. M., Piram, M., & Koné‐Paut, I. (2019) · Springer eBooks · doi:10.1007/978-3-319-98605-0_13
Espinosa-Cotton, M. M., Zhang, W., Weiner, G. J., Simons‐Burnett, A. L., Gibson-Corley, K. N., & Spitz, D. R. (2018) · doi:10.17077/etd.ozas-ciug
Avaliação do eixo IL-1/IL-1R na comorbidade obesidade e tuberculose
de Oliveira, R. S. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2019.tde-15102018-113326
Melehani, J. H. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dnpd-f156 · Cited by 1
Criopirinopatías: ¿qué son?, ¿cómo detectarlas? y ¿cuál es el enfoque de su tratamiento?
Gallego, M., Jaramillo, C., Sierra, J., & Velásquez, M. M. (2019) · Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica · doi:10.29176/2590843x.983
Groslambert, M. (2019) · theses.fr (ABES) · doi:10.70675/7ec36fdaz7c33z4ac3z8f3azf6a7d1320f06
Cabrera, N., Lega, J., Kassaï, B., Wouters, C. H., Kondi, A., Cannizzaro, E., Woerner, A., Chausset, A., Roethlisberger, S., Jeanneret, C., et al. (2019) · Revue du Rhumatisme · doi:10.1016/j.rhum.2019.11.014
Kriulin, I. A., Alexeeva, E. I., Dvoryakovskaya, T. M., Ибрагимовна, Б. Б., Savostyanov, K. V., Zhurkova, N. V., Pushkov, A. A., Владимирович, А. А., & Nesterov, A. M. (2019) · Вопросы современной педиатрии · doi:10.15690/vsp.v18i4.2044
Phenotypic and clinical outcome studies in amyloidosis and associated autoinflammatory diseases
Youngstein, T. (2019) · UCL Discovery (University College London) · Cited by 1
Touitou, I. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.03.010
IL-1 mediated autoinflammatory diseases
de Jesus, A. A., Ferguson, P. J., & Goldbach‐Mansky, R. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816768-7.00028-4
Hereditary diseases that should be differentiated from urticaria
Kanazawa, N. (2020) · Nihon Shoni Arerugi Gakkaishi The Japanese Journal of Pediatric Allergy and Clinical Immunology · doi:10.3388/jspaci.34.253
Chronic urticarial plaques in a young woman
Ward, S. C., & Rojek, N. W. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.05.038
“It is approved by the US Food and Drug Administration for the treatment of FCAS as well as other periodic fever syndromes, hyperimmunoglobulin D syndrome, systemic juvenile idiopathic arthritis, and adult-onset Still disease.(4,5) Our patient was treated with canakinumab 150 mg administered every 8 weeks and experienc…”
BackgroundPrecision Medicine Concept and its Role in the Treatment of Immunological Diseases
Özer, M., & Bostancı, İ. (2021) · Güncel Pediatri · doi:10.4274/jcp.2021.0032
Visual loss with chronic meningeal and systemic inflammation
Fernandes, P. M., Kinton, L., Madill, S. A., Burgess, F. R., McRorie, E., Dhaun, N., Kidd, D. P., Lachmann, H. J., Davenport, R., & Hunt, D. P. J. (2021) · Practical Neurology · doi:10.1136/practneurol-2021-003066
Self-citationO estado da arte das síndromes autoinflamatórias associadas à criopirina
Pagotto-Betzler, K. R., Chiosini, V., Prado, A. I., Gehlen, B., Castro, F. F. M., Barros, M. T., Kalil, J. E., & Mendonça, L. O. (2021) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20210040
Tan, Q., Yang, Z., Chen, W., & Jin, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-1091297/v1
Navetta‐Modrov, B., Kontzias, A., & Yao, Q. (2021) · Springer eBooks · doi:10.1007/978-3-030-80699-6_12
(2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833c4b2b
(2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834179f9
Ombrello, A. K., & Aksentijevich, I. A. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-389-3_3
Azizi, G., Arshi, S., Nabavi, M., Sadeghi‐Shabestari, M., Suri, D., & Gupta, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821028-4.00007-5
Modern Therapies in AA Amyloidosis
Ombrello, A. K. (2015) · Current clinical pathology · doi:10.1007/978-3-319-19294-9_38
Dusser, P., Marsaud, C., & Koné‐Paut, I. (2016) · EMC - Aparato Locomotor · doi:10.1016/s1286-935x(15)76113-7
Lopez-Escamez, J. A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718874880.793549285
Gram, H. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch50
(2013) · Revue du Rhumatisme · doi:10.1016/s1169-8330(13)70069-3
Metadata
- Authors
- Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N.
- Affiliations
- University College London (GB)
- Universitätsklinikum Tübingen (DE)
- University of California, San Francisco (US)
- Université de Lille (FR)
- Hôpital Necker-Enfants Malades (FR)
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-06-04
- Volume
- 360
- Issue
- 23
- Pages
- 2416-2425
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149374693
- Cited by
- 869
- References
- 19
- Citations by year
- 2026: 23 · 2025: 30 · 2024: 31 · 2023: 23 · 2022: 37 · 2021: 40 · 2020: 53 · 2019: 56 · 2018: 34 · 2017: 38 · 2016: 55 · 2015: 67 · 2014: 50 · 2013: 66 · 2012: 73
- FWCI
- 35.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- canakinumab, cryopyrin-associated periodic syndromes, IL-1β, interleukin-1 receptor antagonist, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, disease flares, C-reactive protein, serum amyloid A, infection risk, urosepsis, vertigo, treatment withdrawal
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Adolescent, Adult, Aged, Antibodies, Monoclonal, Carrier Proteins, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Familial Mediterranean Fever, Interleukin-1beta, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.